Search Tufts Medicine

Displaying 161 - 165 of 165
clinical trial
...

This is a non-randomized, open label, multi-site, single dose, Phase 3 study in approximately 35 adults and pediatric subjects > 2 and < 50 years of ages with SCD. The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using LentiGlobin BB305 Drug Product, an autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector (LVV) encoding beta A-T87Q-globin gene, suspended in cryopreservation solution in the final immediate container for the intended medical use.
clinical trial
...

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Articles
August 7, 2024
Understand heart attack signs, symptoms, and prevention. Discover risk factors and learn what to do during a heart attack from the team at Tufts Medicine.
department
The Department of Pathology and Laboratory Medicine provides comprehensive testing and analysis services across all aspects of anatomic and clinical pathology, as well as blood bank analyses. Thousands of specimens land in our labs each day, each sample containing valuable diagnostic information about medical conditions and how to best treat them.